Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series

Figures & data

Figure 1: Psoriasis involving the face (Figure 1(a)) and genitals (Figure 1(b)) of a 12-year-old boy before the start of ustekinumab.

Figure 2. Erythematous follicular patches on the back (Figure 2(a)) and left shoulder (Figure 2(b)) after 18 months of treatment with ustekinumab.

Figure 3. Complete skin clearance after 16 weeks of therapy with upadacitinib 15 mg (Figure 3(a,b)).

Table 1. Characteristics of our four patients with concomitant psoriasis and atopic dermatitis receiving upadacitinib.

Patient N	Sex	Age	Psoriatic arthritis	Previous treatments	Upadacitinib dosage	Duration of follow-up (weeks)
1	M	12	No	Ustekinumab, dupilumab	15 mg	52
2	M	39	No	Cyclosporin, brodalumab	15 mg	36
3	F	50	Yes	Salazopyrin, methotrexate, ustekinumab, secukinumab, apremilast	15 mg	32
4	F	42	No	Acitretin, methotrexate, adalimumab, risankizumab, dupilumab	30 mg	60

Data availability statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.